Quick Answer
DNA X, Inc. reported Diluted EPS of $7.13 per share (loss) for fiscal year 2024.
DNA X, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$7.13 | -35550.0% |
| 2023 | -$0.02 | +95.9% |
| 2022 | -$0.49 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.83 | +48.2% | -511.4% |
| June 30, 2025 | -$0.79 | +44.0% | -1087.5% |
| March 31, 2025 | $0.08 | +112.3% | +100.9% |
| September 30, 2024 | -$9.32 | -7866.7% | -561.0% |
| June 30, 2024 | -$1.41 | -1381.8% | -116.9% |
| March 31, 2024 | -$0.65 | -6600.0% | -641.7% |
| September 30, 2023 | $0.12 | +400.0% | +9.1% |
| June 30, 2023 | $0.11 | +150.0% | +1000.0% |
- DNA X, Inc. showed a decrease of -35550.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, DNA X, Inc.’s diluted eps has declined by 1355.1% (from $0.49 per share (loss) to $7.13 per share (loss)).
- The most recent figure is from DNA X, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: